This review highlights that there is still no clear evidence regarding the cost-effectiveness of anti PD-L1 and PD-1 for treating NSCLC, while at present, the available evidence is generally not in favour of the cost-effectiveness of anti PD-L1 in other solid tumours. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.